Source: View source · Endpoints News · web

Why it's worth your time

An AI-first drug developer backed by Nvidia has filed to go public, disclosing pipeline and pharma-partnership detail for the first time; a filing is not a pricing, but a well-received AI biotech IPO is one of the signals the biotech funding-cycle case is waiting on.